The global alpha emitter market size is accounted at USD 696.72 billion in 2025 and is forecasted to hit around USD 1,617.58 billion by 2034, representing a CAGR of 9.78% from 2025 to 2034. The North America market size was estimated at USD 279.96 billion in 2024 and is expanding at a CAGR of 9.80% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Alpha Emitter Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Alpha Emitter Market, by Type of Radionuclide
8.1.1 Radium (Ra-223)
8.1.1.1. Market Revenue and Forecast
8.1.2. Actinium (Ac-225)
8.1.2.1. Market Revenue and Forecast
8.1.3. Lead (Pb-212)
8.1.3.1. Market Revenue and Forecast
8.1.4. Astatine-211
8.1.4.1. Market Revenue and Forecast
8.1.5. Bismuth-213
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Alpha Emitter Market, by Application
9.1.1. Bone Metastases
9.1.1.1. Market Revenue and Forecast
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Neuroendocrine Tumors
9.1.3.1. Market Revenue and Forecast
9.1.4. Ovarian Cancer
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Alpha Emitter Market, by Source
10.1.1. Natural Sources (Uranium-238, Radium-226)
10.1.1.1. Market Revenue and Forecast
10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Radionuclide
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by Source
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by Source
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by Source
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Radionuclide
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by Source
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by Source
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by Source
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by Source
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by Source
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Radionuclide
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by Source
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by Source
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by Source
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by Source
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by Source
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by Source
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by Source
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by Source
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by Source
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by Source
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by Source
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by Source
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by Source
12.1. Alpha Tau Medical Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. NorthStar Medical Radioisotopes
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IBA Worldwide
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. RadioMedix
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Orano Med
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis International AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Actinium Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fusion Pharmaceuticals Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eckert & Ziegler
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample